


ISLHD CANCER CLINICAL TRIALS NEWSLETTER

April 2022

ISLHD CANCER CLINICAL TRIALS UNIT

Illawarra Cancer Care Centre
Wollongong Hospital
Loftus Street
Wollongong NSW 2500

Clinical Trials available through the Illawarra Shoalhaven Local Health District can be found on the Oncology NSW ClinTrial Refer App on iTunes and Google Play.



The Illawarra Shoalhaven Local Health District (ISLHD) Cancer Clinical Trials Unit has a specialist team of doctors, nurses, radiation therapists and allied health professionals supporting a comprehensive suite of clinical trials for our local community. We are based at Wollongong Hospital in the Illawarra Cancer Care Centre and Shoalhaven Hospital in the Shoalhaven Cancer Care Centre.

Clinical trials contribute to evidence based practice, knowledge development and improved patient care. They provide our patients the opportunity to access novel and potentially efficacious treatment for their cancer close to home.

We currently have trials open for patients with:

- Chemotherapy induced nausea and vomiting
- Prostate cancer
- Colorectal cancer
- Breast cancer
- Pancreatic cancer
- Head and Neck cancer
- Endometrial cancer
- Oesophageal cancer
- Gastro-oesophageal cancer
- Neuroendocrine cancer
- Lung cancer
- Brain cancer

REFERRAL OR CONSULTATION

To discuss your patients treatment options with an ISLHD

Oncology Trials Clinician, please call:


Illawarra Cancer Care Center 02 4222 5200

Clinical Trials Unit

Phone: +61 2 42534384





Fax: +61 2 42225085

Email: ISLHD-CancerClinicalTrials@health.nsw.gov.au



ISLHD ONCOLOGY CLINICAL TRIALS OPEN FOR RECRUITMENT








ISLHD-CancerClinicalTrials@health.nsw.gov.au — Phone: +61 2 42534384

TUMOR GROUP	<i>Use the hyperlink in study name or scan QR code to find out more eligibility information</i>		
GI/Biliary	<p>Astellas Pancreas: A phase II, open-label, randomized study to assess the efficacy and safety of zolbetuximab (IMAB362) in combination with nab-paclitaxel and gemcitabine (Nab-P + GEM) as first line treatment in subjects with claudin 18.2 (CLDN18.2) positive, metastatic pancreatic adenocarcinoma.</p>	Dr Chantrill Taylor Feast	
	<p>DYNAMIC III: Circulating tumour DNA analysis informing adjuvant chemotherapy in stage III colon cancer: a multi-centre phase II/III randomised controlled study.</p>	Prof Aghmesheh Megan Power	
	<p>OXTOX: Can oxaliplatin neurotoxicity be reduced with ibudilast in people with metastatic colorectal cancer – a phase II randomised study.</p>	Dr Chantrill Tia Summerside (ICCC) Kyrie Rodgers (SCCC)	
	<p>NEOCREATE: Neoadjuvant immune-chemo-radiotherapy in operable oesophageal and gastro-oesophageal junction cancers with carboplatin paclitaxel radiotherapy and avelumab – a trial assessing feasibility and preliminary efficacy.</p>	Dr Chantrill Tia Summerside	
	<p>NEO-IMPACT: NEO-adjuvant chemo-IMmunotherapy in PAnCreaTic cancer.</p>	Dr Chantrill Taylor Feast	
	<p>LEAP-015: Phase 3, randomized study to evaluate the efficacy and safety of lenvatinib (E7080/MK-7902) plus pembrolizumab (MK-3475) plus chemotherapy compared with standard of care therapy as first-line intervention in participants with advanced/metastatic gastroesophageal adenocarcinoma.</p>	Dr Brungs Taylor Feast	



ISLHD ONCOLOGY CLINICAL TRIALS OPEN FOR RECRUITMENT






ISLHD-CancerClinicalTrials@health.nsw.gov.au — Phone: +61 2 42534384

TUMOR GROUP	<i>Use the hyperlink in study name or scan QR code to find out more eligibility information</i>		
Breast	<p>EXPERT: A randomised Phase III trial of adjuvant radiation therapy versus observation following breast conserving surgery and endocrine therapy in patients with luminal A early breast cancer.</p> <p>BRCA-P: A randomised, double blind, placebo-controlled, phase 3 study to determine the preventive effect of denosumab on breast cancer in women carrying a BRCA1 germline mutation.</p> <p>FINER: A double-blind, placebo-controlled, randomized phase III trial of fulvestrant and ipatasertib as treatment for advanced HER-2 negative and estrogen receptor positive (ER+) breast cancer following progression on first line CDK 4/6 inhibitor and aromatase inhibitor.</p>	<p>Dr Fox Jo Boynton Elise Cardoso</p> <p>Dr Aghmesheh Tia Summerside</p> <p>Dr Mapagu Kyrie Rodgers</p>	  
GU	<p>NINJA: Novel Integration of New prostate radiation schedules with adjuvant Androgen deprivation for patients with intermediate or low-high risk prostate cancer.</p> <p>DASL-HiCaP: Darolutamide augments standard therapy for localised very high-risk cancer of the prostate (ANZUP1801). A randomized phase 3 double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation in very high risk, clinically localised prostate cancer.</p> <p>CONTACT-02: A phase 3, randomised, open-label, controlled study of cabozantinib (XL184) in combination with atezolizumab vs second novel hormonal therapy (NHT) in subjects with metastatic castration-resistant prostate cancer.</p>	<p>Prof Miller Lucy Sutton</p> <p>Dr Gandhidasan Chris Pobersnik (ICCC) Kyrie Rodgers (SCCC)</p> <p>Dr Brungs Megan Power</p>	  
H&N	<p>TrilynX: A randomized, double-blind placebo-controlled, phase 3 study of Debio 1143 in combination with platinum-based chemotherapy and standard fractionation intensity modulated radiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck, suitable for definitive chemoradiotherapy.</p>	<p>Dr Aghmesheh Tia Summerside</p>	



ISLHD ONCOLOGY CLINICAL TRIALS OPEN FOR RECRUITMENT

ISLHD-CancerClinicalTrials@health.nsw.gov.au — Phone: +61 2 42534384

TUMOR GROUP	<i>Use the hyperlink in study name or scan QR code to find out more eligibility information</i>		
Skin	<p>CPOST: A randomised, placebo-controlled, double-blind study of adjuvant cemiplimab versus placebo after surgery and radiation therapy in patients with high risk cutaneous squamous cell carcinoma.</p>	<p>Dr Brungs Chris Pobersnik (ICCC) Kyrie Rodgers (SCCC)</p>	
Lung	<p>ARC-7: A Phase 2 study to evaluate the safety and efficacy of AB122 monotherapy, AB154 in combination with AB122, and AB154 in combination with AB122 and AB928 in front-line, non-small cell lung cancer.</p>	<p>Dr Brungs Kyrie Rodgers (SCCC)</p>	
Brain	<p>MAGMA: The multi-arm glioblastoma Australasia (MAGMA) trial. This trial aims to assess whether or not to give a cycle of temozolomide prior to chemoradiotherapy, and whether to give 6 or 12 cycles of temozolomide after chemoradiotherapy.</p>	<p>Dr Brungs Chris Pobersnik</p>	
Solid Tumours	<p>M20-111: A Phase 1 first in human study evaluating safety and efficacy of ABBV-637 as either monotherapy or in combination in adult subjects with relapsed and refractory solid tumors.</p> <p>PORCUPINE2: A modular, phase II, open-label, multicentre study to assess the preliminary efficacy and safety of RXC004, in patients with advanced solid tumours that have progressed following therapy with current standard of care.</p>	<p>Dr Brungs Tia Summerside</p> <p>Dr Chantrill Tia Summerside/ Chris Pobersnik/ Megan Power</p>	 
Other	<p>Cannabis CINV: Pilot and definitive randomised double-blind placebo-controlled trial evaluating oral cannabis for secondary prevention of chemotherapy-induced nausea and vomiting (CINV).</p> <p>CARE NSW: Cannabinoids for symptom control in advanced cancer, an open label prospective clinical trial in NSW.</p>	<p>Dr Aghmesheh Tia Summerside/ Taylor Feast</p> <p>Dr Mapagu Tia Summerside/ Taylor Feast (ICCC) Kyrie Rodgers (SCCC)</p>	